Effect of Nutritional Indices on the Prognosis of HCC Patients

NCT05635279 | Completed

• 1 other identifier: 2022-182
• Study Type: observational
• Target: 150
• Locations: 1 country
• Sites: 1

Brief Summary

Primary liver cancer has recently ranked among the leading causes of cancer death, with hepatocellular carcinoma (HCC) accounting for 75%-85% of these cases. In recent years, immune checkpoint inhibitors (ICIs) combined with tyrosine kinase inhibitors (TKIs) have achieved good results in the treatment of advanced HCC patients. So far, there is a lack of studies exploring the relationship between nutritional index and the prognosis of HCC patients treated with ICIs combined with TKIs, and there are few studies on the prognostic value of nutritional index in HCC patients treated with transarterial chemoembolization (TACE). This retrospective study aims to analyze the prognostic value of prognostic nutritional index(PNI)，body mass index (BMI), psoas muscle index（PMI）and geriatric nutritional risk index (GNRI) in HCC patients who received ICIs combined with TKIs or TACE, and to provide reference for the selection of nutritional intervention programs for HCC patients.

Conditions

Hepatocellular Carcinoma

Keywords

prognostic nutritional index; psoas muscle index; geriatric nutritional risk index; prognosis

Outcome Measures

Primary Outcomes (1)

• Death

  Death due to hepatocellular carcinoma progression

  November 2022 to May 2024

Secondary Outcomes (1)

• Censored

  November 2022 to May 2024

Study Arms (2)

HCC patients who received ICIs combined with TKIs

HCC patients who received ICIs combined with TKIs regularly and periodically.

HCC patients treated with TACE

HCC patients who underwent TACE as initial treatment.

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients who confirmed HCC in the Second Affiliated Hospital of Chongqing Medical University were enrolled in the retrospective study. The subjects were divided into two cohorts, both of which met the inclusion and exclusion criteria.

You may qualify if:

• Cohort 1:HCC patients received ICIs combined with TKIs regularly and periodically.
• Cohort 2:HCC patients who underwent TACE as initial treatment.

You may not qualify if:

• Patients with systemic malignant tumors other than HCC.
• Patients with severe hypertension, diabetes, coronary heart disease, systemic infection and other serious diseases.
• patients with immunodeficiency or autoimmune diseases.
• Patients with severe malnutrition.
• Not adhering to regular and periodic treatment.
• Patients without regular follow-up or with missing data to be collected.

Sponsors & Collaborators

• Juan Kang: lead

Study Sites (1)

The Second Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, 400000, China

Location

Related Publications (1)

• Luo N, Li H, Luo Y, Hu P, Liang L, Zhang R, Zhang D, Cai D, Kang J. Prognostic significance of psoas muscle index in male hepatocellular carcinoma patients treated with immune checkpoint inhibitors and tyrosine kinase inhibitors. Hum Vaccin Immunother. 2023 Aug;19(2):2258567. doi: 10.1080/21645515.2023.2258567. Epub 2023 Sep 20.

  PMID: 37728115 DERIVED

MeSH Terms

Conditions

Carcinoma, Hepatocellular

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Liver Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Liver Diseases

Study Officials

• Juan Kang, M.D.

  The Second Affiliated Hospital of Chongqing Medical University

  STUDY CHAIR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: associate professor

Study Record Dates

• First Submitted: November 22, 2022
• First Posted: December 2, 2022
• Study Start: November 1, 2022
• Primary Completion: January 7, 2023
• Study Completion: May 9, 2023
• Last Updated: June 25, 2025

Record last verified: 2025-06

Locations

CN (1)